ChromaDex Corporation (NAGE) - Multiplikator forward rega marang pendapatan
Sales diversification across B2B and B2C segments ensures a stable cash flow from recurring contracts, and the GURU.Markets platform provides this chart of the company's projected P/S, where 4.60 represents the current metric. The monopoly position of Chromadex Corp (NAGE) in the cellular health niche is based on the ownership of fundamental patents and regulatory approvals.
ChromaDex Corporation - rincian analitis lan metrik utama (NAGE)
- rega pasar lan target rega analis:
- indikator kapitalisasi pasar:
- rincian valuasi buku bisnis:
- indikator beban kredit lan likuiditas emiten:
Utang marang Ekuitas Chromadex Corp|NAGE - Rasio utang jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas Chromadex Corp|NAGE - Tanggungan utang kumulatif perusahaan|Rasio utang marang kapitalisasi buku ChromaDex Corporation|NAGE - Gunggunge utang jangka dawa|Utang jangka cendhak perusahaan ChromaDex|Rasio cepet niagenbioscience.com
- data bathi bisnis lan rasio investasi:
NAGE - Bathi pungkasan|Bathi sing dikarepake Chromadex Corp|NAGE - Nilai perusahaan marang bathi resik|Rega marang bathi mangsa ngarep ChromaDex Corp.|NAGE - Rega marang bathi kanthi panyesuaian wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan ChromaDex Corporation|NAGE - Bathi operasional sadurunge ngurangi amortisasi|Bathi resik saben saham (EPS TTM) ChromaDex|NAGE - Bathi resik saben saham (EPS TTM)|Wutah bathi EPS kuartalan niagenbioscience.com|NAGE - Wutah bathi saben saham ing taun iki|Prakiraan wutah bathi kanggo taun ngarep Chromadex Corp
- data dodolan lan asil:
Analisis umum perusahaan:NAGE (ChromaDex)
The forward P/S ratio relates current market capitalization to projected annual revenue, determining the premium for expected business growth. By analyzing the forward P/S trajectory, an investor assesses the risk of asset overvaluation should expansion slow. High multiplier values are justified by the exclusive ownership of Niagen patents. This allows Chromadex Corp (NAGE) to maintain pricing power in the cellular rejuvenation sector, supporting high sales margins.
Analisis perusahaan pesaing
Rasio rega marang prakiraan pendapatan Intuitive ISRG|Rega forward marang dodolan DHR|BDX: Multiplikator forward rega marang pendapatan|STE - Multiplikator Forward P/S|West Pharmaceutical Services (WST) - Rasio rega marang prakiraan pendapatan|Multiplikator forward rega marang pendapatan baxter.com|MASI (Masimo) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Stevanato Group SpA STVN|Rasio rega marang prakiraan pendapatan Teleflex Inc (TFX)|Merit Medical Corp - Kapitalisasi marang prakiraan pendapatan|Envista Holdings - Multiplikator forward rega marang pendapatan|Rasio rega marang pendapatan sing dikarepake ICUI (icumed.com)|XRAY - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake LeMaitre Vascular Inc LMAT|ATRC: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan STAAR Surgical Co|ZIMV (ZimVie Inc.) - Multiplikator Forward P/S|ANGO: Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Cerus (CERS)|TKNO (Alpha Teknova) - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Monogram Technologies Inc MGRM|Sharps Technology Inc (STSS) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|INFU - Rasio rega marang prakiraan pendapatan|utahmed.com (UTMD) - Multiplikator forward rega marang pendapatan|KRMD: Multiplikator Forward P/S|Nyxoah SA (NYXH) - Multiplikator Forward P/S|MBOT (Microbot Medical Inc) - Multiplikator Forward P/S|Kapitalisasi marang prakiraan pendapatan PDEX (Pro-Dex Inc.)|Multiplikator Forward P/S ZTEK|ELUT - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Milestone Scientific Inc. - Multiplikator forward rega marang pendapatan|NXGL: Kapitalisasi marang prakiraan pendapatan|RVP: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan HBIO (harvardbioscience.com)|FEMY: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Meihua Medical Technologies Co., Ltd.|Rasio rega marang prakiraan pendapatan Predictive Oncology Inc|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Callan JMB Corp CJMB|Rasio rega marang prakiraan pendapatan Atrion Corp (ATRI)|NURO (NeuroMetrix Corporation) - Rega forward marang dodolan
